IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
© 2023. The Author(s)..
BACKGROUND: Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to investigate the prognostic significance of IL-6 serum levels before and during treatment.
METHODS: Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study.
RESULTS: Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients whose IL-6 level increased after treatment with cemiplimab, independently of the basal level, had a poorer response to treatment than patients whose level was reduced or stable after immunotherapy.
CONCLUSIONS: Serum levels of IL-6 at baseline and changes after cemiplimab immunotherapy may have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 21(2023), 1 vom: 23. Feb., Seite 140 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mallardo, Domenico [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6QVL057INT |
|---|
| Anmerkungen: |
Date Completed 27.02.2023 Date Revised 26.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12967-023-03971-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353299022 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353299022 | ||
| 003 | DE-627 | ||
| 005 | 20231226055655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-023-03971-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353299022 | ||
| 035 | |a (NLM)36823670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mallardo, Domenico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2023 | ||
| 500 | |a Date Revised 26.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. The aim was to investigate the prognostic significance of IL-6 serum levels before and during treatment | ||
| 520 | |a METHODS: Serum levels of IL-6 were correlated with clinical outcomes in a retrospective study | ||
| 520 | |a RESULTS: Overall, 39 patients were enrolled. High serum levels of IL-6 (> 5.6 pg/ml) were associated with poorer survival (45.1% vs 0 deaths; OS: 16.1 ± 1.5 vs 20.8 ± 0 months, 95% CI 13,046 to 19,184) and shorter PFS (10.3 ± 1.9 vs 18.9 ± 1.5 months; 95% CI 3433 to 10,133) in patients with advanced CSCC treated with cemiplimab. In addition, patients whose IL-6 level increased after treatment with cemiplimab, independently of the basal level, had a poorer response to treatment than patients whose level was reduced or stable after immunotherapy | ||
| 520 | |a CONCLUSIONS: Serum levels of IL-6 at baseline and changes after cemiplimab immunotherapy may have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cemiplimab | |
| 650 | 4 | |a Cutaneous squamous cell carcinoma | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a Prognostic factor | |
| 650 | 7 | |a cemiplimab |2 NLM | |
| 650 | 7 | |a 6QVL057INT |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 700 | 1 | |a Simeone, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Festino, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Tuffanelli, Marilena |e verfasserin |4 aut | |
| 700 | 1 | |a Vanella, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Trojaniello, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Vitale, Maria Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Ottaviano, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Capone, Mariaelena |e verfasserin |4 aut | |
| 700 | 1 | |a Madonna, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Sparano, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Cioli, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpato, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Palla, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Di Trolio, Rossella |e verfasserin |4 aut | |
| 700 | 1 | |a Meinardi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Caracò, Corrado |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Gerardo |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalcanti, Ernesta |e verfasserin |4 aut | |
| 700 | 1 | |a Ascierto, Paolo Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d 2003 |g 21(2023), 1 vom: 23. Feb., Seite 140 |w (DE-627)NLM142679194 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:1 |g day:23 |g month:02 |g pages:140 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12967-023-03971-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 1 |b 23 |c 02 |h 140 | ||